Heart failure is independently associated with white matter lesions: insights from the population-based LIFE-Adult Study Tina Stegmann MD1*†, Mai L. Chu2†, Veronica A. Witte PhD3, Arno Villringer MD3, Deniz Kumral MSc3, Steffi G. Riedel-Heller MD4, Susanne Roehr MSc4, Andreas Hagendorff MD1, Ulrich Laufs MD1, Markus Loeffler MD2,7, Rolf Wachter MD1,5,6† and Samira Zeynalova PhD1,7† 1Clinic and Policlinic for Cardiology, University Hospital Leipzig, Leipzig, Germany; 2University of Leipzig, Institute for Medical Informatics, Statistics and Epidemiology (IMISE), Leipzig, Germany; 3Department of Neurology, Max Planck Institute for Human Cognitive and Brain Science, Leipzig, Germany; 4Public Health Research Unit and Department of Social Medicine, University of Leipzig, Leipzig, Germany; 5Clinic for Cardiology and Pneumology, University Medicine Göttingen, Göttingen, Germany; 6German Cardiovascular Research Center (DHZK), partner site Göttingen, Göttingen, Germany; 7University of Leipzig, LIFE - Leipzig Research Centre for Civilization Diseases, Leipzig, Germany Abstract Aims White matter lesions (WML) are common structural alterations in the white matter of the brain and their prevalence increases with age. They are associated with cerebral ischaemia and cognitive dysfunction. Patients with heart failure (HF) are at risk for cognitive decline. We hypothesized that the presence and duration of HF are associated with WML. Methods and results The LIFE-Adult Study is a population-based study of 10 000 residents of Leipzig, Germany. WML were quantitated in 2490 participants who additionally underwent cerebral MRI using the Fazekas score. Mean age was 64 years, and 46% were female; 2156 (86.6%) subjects had Fazekas score of 0–1, and 334 (13.4%) had Fazekas score of 2–3. Thirty participants had a medical history of HF, 1019 had hypertension, and 51 had a history of stroke. Median left ventricular ejection fraction of the participants with HF was 57% (interquartile ranges 54–62). Age, troponin T, NT-proBNP, body mass index, history of acute myocardial infarction, stroke, HF, and diabetes were positively associated with WML in univariate analysis. On multivariate analysis, age, hypertension, stroke, and HF were independently associated with WML. The odd’s ratio for the association of WML (Fazekas 2–3) with HF was 2.8 (95% CI 1.2–6.5; P = 0.019). WML increased with longer duration of HF (P = 0.036 for trend). Conclusions In addition to age, hypertension, and stroke, the prevalence and duration of HF are independently associated with WML. This observation sets the stage to investigate the prognostic value of WML in HF and the impact of HF therapies on WML. Keywords Heart failure; White matter lesions; Cognitive impairment; Magnetic resonance imaging; Population-based study Received: 25 September 2020; Revised: 10 November 2020; Accepted: 23 November 2020 *Correspondence to: Dr. med. Tina Stegmann, Universitätsklinikum Leipzig Klinik und Poliklinik für Kardiologie Liebigstraße 20, 04103 Leipzig. Tel.: +49 341 9720972; Fax: +49 341 9712688. Email: Tina.Stegmann@medizin.uni-leipzig.de †These authors contributed equally to this work. Introduction White matter lesions (WML), also called white matter hyperintensities, are common in the elderly with or without neurological symptoms.1,2 They appear hyperintense on T2-weighted magnetic resonance imaging (MRI) and are considered as a type of sporadic small vessel diseases, typi- cally affecting periventricular regions and deep white matter sparing U-fibres.3,4 While age and arterial hypertension are strong predictors of WML, they are linked to various vascular risk factors and cerebrovascular diseases and are related to a three-fold increase in risk for stroke.5–7 A high burden of WMLs was found to be negatively associated with cognitive function and to the physical function.8–13 Cross-sectional and prospective studies further indicated a relation between WML and the onset of dementia.7,14 Importantly, the OR IG INAL RESEARCH ART ICLE © 2020 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. ESC HEART FAILURE ESC Heart Failure 2021; 8: 697–704 Published online 15 December 2020 in Wiley Online Library (wileyonlinelibrary.com) DOI: 10.1002/ehf2.13166 mailto:Tina.Stegmann@medizin.uni-leipzig.de http://creativecommons.org/licenses/by-nc-nd/4.0/ http://crossmark.crossref.org/dialog/?doi=10.1002%2Fehf2.13166&domain=pdf&date_stamp=2020-12-15 prevalence of cognitive impairment is increased in patients with cardiovascular diseases. There is consistent evidence that cognitive impairment is highly prevalent in patients with heart failure (HF).15–17 In previous reports and meta-analyses, the prevalence for cognitive deficits among patients with HF varies from 25% to 80%, depending on the study design and the study population.17,18 The cognitive deficits in patients with HF are characterized by increased al- terations in the domains of attention, verbal memory, and emotional processing.19,20 As structural correlates, medial temporal lobe atrophy (MTA), grey matter loss (GM), and WML have been reported in patients with HF using cerebral MRI (cMRI) scans.1,19,20 To date, there are few studies on HF and the risk for structural brain damage; however, the findings are limited due to the study designs, which included mostly a high-risk population group compared with a selected control group. The association of WML with cardiovascular risk factors and with HF in an unselected population remains elusive. Therefore, the purpose of the present study was to analyse the association between cardiovascular risk factors, HF, and WML in a population-based cohort study, the LIFE-Adult Study (The Leipzig Research Centre for Civilization Diseases). Methods Study population The LIFE-Adult Study, as part of the ‘Leipzig Research Center for Civilization Diseases’ (LIFE), is a population-based cohort study with 10 000 randomly selected residents from Leipzig (age ranged from 18–80 years), a city in the eastern part of Germany (approximately 600 000 inhabitants).21 The study constituted an age and gender stratified sample as described previously.22 All subjects signed an informed consent form, and the study protocol was in accordance with the Declaration of Hel- sinki and approved by the Ethics Committee of the University of Leipzig. The study was initiated to evaluate the prevalence, early onset markers, genetic predispositions, and the role of lifestyle factors of major civilization diseases. Metabolic and vascular diseases, heart function, and cognitive impairment are also in the central focus of the LIFE project.22 All subjects underwent an extensive core assessment pro- gram (5–6 h) including structured medical interviews, medical and psychological questionnaires, physical examination, and bio specimen collection.22 Heart function Heart failure was defined by the self-reported diagnosis from the medical questionnaires, or rather, participants were asked if they have ever been diagnosed with HF by a physician. To further describe potential arrhythmias or to specify the heart function, a 12-lead electrocardiogram (ECG, Page-Writer TC50® ECG system, Philips Medical Systems GmbH, Hamburg, Germany) was used to investigate cardiac arrhythmias, and echocardiography was used to obtain a phenotyping of the heart function to investigate the different types of HF (systolic vs. diastolic dysfunction). The ECGs were separately evaluated for atrial fibrillation (AF) by two independent evaluators. Echocardiography was one of the routine examinations in LIFE Adult and was performed using the GE Vivid 7 dimension BTO8 echocardiog- raphy station (GE Healthcare, Chicago, Illinois, USA), accord- ing to the recommendations of the American Society of Echocardiography (ASE) and the European Society of Cardiology (ESC).22 For this analysis, left ventricular ejection fraction (LVEF, Simpson’s biplane method was used and computed by biplane 2D measurements) as systolic func- tional parameter and E/E′ as diastolic function parameter was used for evaluation. Magnetic resonance imaging and Fazekas score A total of 2490 participants additionally underwent MRI of the head. The cMRI scans were performed at 3-Tesla on a MAGNETOM Verio Scanner (Siemens, Erlangen, Germany). T1-weighted MPRAGE and FLAIR images were acquired as part of a standardized protocol: MPRAGE [flip angle (FA) = 9°, relaxation time (TR) = 2300 ms, inversion time (TI) = 900 ms, echo time (TE) = 2.98 ms, 1 mm isotropic reso- lution, acquisition time (AT) = 5.10 min]; FLAIR (TR = 5,000 ms, TI = 1800 ms, TE = 395 ms, 1 × 0.49 × 0.49 mm resolution, AT = 7.02 min). Structural MRI parameters were used for identifying neurodegenerative diseases, and WML have been analysed/acquired by an auto- mated assessment such that higher score reflects the increased overall burden of cerebral WML.23 WML were rated by using the Fazekas score (the scale ranges from 0 to 3), which reflects the overall burden of WML.24,25 The Fazekas score is a visual rating of WML and is used in every day clinical practice.26 Rating score 0 is defined by no lesions and represents a ‘healthy brain’. Score 1 describes focal lesions. Fazekas 0 and 1 are common in the elderly and are in most cases asymptomatic. The beginning of confluence lesions is defined by rating score 2 and diffuse involvement of the entire region is rated by score 3. Fazekas scores 2 and 3 are associated with cognitive dysfunction.26 The volume of the white matter was adjusted to the volume of the head. 698 T. Stegmann et al. ESC Heart Failure 2021; 8: 697–704 DOI: 10.1002/ehf2.13166 20555822, 2021, 1, D ow nloaded from https://onlinelibrary.w iley.com /doi/10.1002/ehf2.13166 by M assey U niversity L ibrary, W iley O nline L ibrary on [21/11/2023]. See the T erm s and C onditions (https://onlinelibrary.w iley.com /term s-and-conditions) on W iley O nline L ibrary for rules of use; O A articles are governed by the applicable C reative C om m ons L icense Neurocognitive testing Participants older age (>60 years) underwent additionally neurocognitive testing at baseline examination. The Trail- Making-Test (TMT) A and B, as subtests of the CERADplus test, have been evaluated for this analysis. These are part from an extended neuropsychological test battery of the Consortium to Establish a Registry for Alzheimer’s Disease.27,28 The TMT A and B are used to identify deficits in attention, perceptual speed, cognitive flexibility, and exec- utive function. TMT measures speed and mental flexibility.29 Basically, in the first part of the test (TMT-A), the targets are all numbers, while in the second part (TMT-B), partici- pants need to alternate between numbers and letters. The TMT was evaluated according to the execution times in seconds for adults specified in the manual.30,31 Importantly, in both TMT-A and B, the time to complete the task quan- tifies the performance; therefore, lower scores indicate better performance.30,31 In this study, the measured time required to perform the tests was analysed in relation to the individual factors. Statistical analysis Data analysis was performed using SPSS version 25 for Windows (IBM, Chicago, USA). Continuous variables are given as mean ± standard devia- tion (SD) or as median with interquartile ranges (25th–75th). Student’s t-test or non-parametric tests (Mann–Whitney U-test) were used for continuous variables. Categorical data are given as numbers of patients (%) and were compared using χ2 test or Fishers’ exact test (if necessary). Binary regression model with WML Fazekas score 0–1 vs. 2–3 as the dependent variables was used for univariate and multivariate analyses. The natural logarithm of NT-proBNP values was used in univariate and multivariate analyses. Variables that showed a significant correlation in univariate analysis and may be clinically important were entered into multiple binary regression model. Linear regression models were used for the cognitive tests.32 The two-sided P-value <0.05 was considered as statistically significant. For selected comparisons between groups, the odds ratio (OR) or regres- sion coefficient (RC) with 95% confidence interval (CI) are presented. Results Baseline characteristics A total of 2490 individuals with cMRI were included in the full analysis. Nine hundred sixty-five participants (38.8%) had Fazekas score 0, 1191 (47.8%) had Fazekas score 1, 290 (11.6%) had Fazekas score 2, and 44 (1.8%) had Fazekas score 3, respectively. For further analysis, patients were stratified into two groups: none or mild WML [Fazekas 0–1, 2156 (86.6%) of the participants] vs. moderate or severe WML [Fazekas 2–3, 334 (13.4%) of the participants]. The baseline characteristics subdivided into the two groups Fazekas 0–1 vs. Fazekas 2–3 are presented in Table 1. Individuals with more WML (Fazekas 2–3) were older, had more comorbidities (hypertension, diabetes, and atrial fibrillation), more often a history of stroke, myocardial infarction, or HF and higher plasma levels of troponin T and NT-proBNP. Table 1 Baseline characteristics of the study participants with cerebral magnetic resonance imaging (cMRI) stratified by the Fazekas score 0–1 and 2–3, respectively Factors FAZEKAS Grade 0 and 1 (n = 2156) Grade 2 and 3 (n = 334) P-value Median age, year (quantiles) 63 (46;70) 71 (66;75) ≤0.001 Female sex, no. (%) 994 (46.6%) 142 (43.0%) 0.221 BMI ≥ 25 no. (%) Normal 750 (35.2%) 81 (24.6%) ≤0.001 Pre-obesity 920 (43.2%) 139 (42.2%) Obesity 458 (21.5%) 109 (33.1%) Smoking, no. (%) 322 (15.7%) 40 (13.1%) 0.247 Myocardial infarction, no. (%) 17 (0.8%) 9 (2.8%) 0.003 Stroke, no. (%) 32 (1.5%) 19 (5.8%) ≤0.001 Heart failure, no. (%) 18 (0.9%) 12 (4.0%) ≤0.001 Diabetes, no. (%) 216 (10.2%) 58 (17.7%) ≤0.001 Hypertension, no. (%) 799 (41.6%) 220 (72.8%) ≤0.001 Troponin T (in pg/mL), median (quantiles) 5 (3;7) 7 (4.8;10.3) ≤0.001 NT-proBNP (in pg/mL), median (quantiles) 64.7 (34.4;113.9) 105.4 (55.6;178.2) ≤0.001 AF in 12-lead ECG, no. (%) 27 (1.2%) 11 (3.3%) 0.005 AF, Atrial fibrillation; BMI, Body Mass Index; ECG, electrocardiogram; NT-proBNP, N-terminal pro-B-type natriuretic peptide. Heart failure is independently associated with white matter lesions: insights from the population-based LIFE-Adult Study 699 ESC Heart Failure 2021; 8: 697–704 DOI: 10.1002/ehf2.13166 20555822, 2021, 1, D ow nloaded from https://onlinelibrary.w iley.com /doi/10.1002/ehf2.13166 by M assey U niversity L ibrary, W iley O nline L ibrary on [21/11/2023]. See the T erm s and C onditions (https://onlinelibrary.w iley.com /term s-and-conditions) on W iley O nline L ibrary for rules of use; O A articles are governed by the applicable C reative C om m ons L icense Predictors of white matter lesions In the univariate binary regression analysis, age, sex, troponin T, NT-proBNP, body mass index (BMI), history of acute myo- cardial infarction, stroke, HF, AF, hypertension, and diabetes were positively associated with WML (data not shown). In multivariate analysis, older age (OR 1.099, 95% CI 1.078–1.120, P ≤ 0.001), stroke almost reached statistical significance (OR 2.0, 95% CI 1.0–4.1, P = 0.05), hypertension (OR 2.0, 95% CI 1.5–2.8, P < 0.001), smoking (OR 1.9, 95% CI 1.2; 2.9, P = 0.003), and HF (OR 2.8, CI: 1.2–6.5, P = 0.019) were independently associated with severe WML (Fazekas 2–3), Figure 1. The independent association of HF was confirmed when AF was incorporated into the model. Gender, BMI, myocardial infarction, and diabetes were not associated with WML. Duration of heart failure and hypertension Twelve out of 30 participants (40.0%) with HF had WML Fazekas 2–3 as compared with 322 out of 2138 participants without HF (15.1%), P < 0.001. In the end model, age, gender, stroke, hypertension, and HF were included. Longer duration of HF was associated with an increased risk for WML (OR 0.8 for HF-duration <3 years, 95% CI 0.1–7.5; OR 1.6 for HF 4–6 years duration, 95% CI 0.3–9.6 and OR 2.9 for HF diagnosis >6 years, 95% CI 1.1–7.9), P = 0.036 for trend, Table 2. Hypertension was also correlated with increased risk of WML, but the risk was independent from the duration of hypertension [Table 3, OR 2.0 for hypertension duration <3 years (vs. no hypertension), OR 2.2 for hypertension dura- tion 4–6 years, and OR 1.9 for hypertension duration >6 years]. Atrial fibrillation and white matter lesions Thirty-eight out of 2490 participants had AF (1.5%). In univariate analysis, participants with more WML suffered more often from AF. After adjustment for age and gender, AF was no longer independently associated with WML (Figure 2). When including HF in the model, AF remained Figure 1 Multivariate analysis of factors associated with WML (Fazekas 2–3). Odd’s ratio with 95% confidence interval and the respective P-value are shown. Table 2 Multivariate analysis of heart failure duration and other factors independently associated with white matter lesions (Fazekas 2 and 3) Factors Odds ratio P-value Confidence interval (95%) Gender (female) 1.1 0.660 (0.8–1.4) Age 1.094 ≤0.001 (1.074–1.114) Stroke 2.0 0.034 (1.0–3.9) Hypertension 2.0 ≤0.001 (1.5–2.7) Heart failure (no vs. ≤3 years after diagnosis) 0.8 0.811 (0.1–7.5) Heart failure (no vs. 4–6 years after diagnosis) 1.6 0.580 (0.3–9.6) Heart failure (no vs. >6 years after diagnosis) 2.9 0.036 (1.1–7.9) BMI, body mass index. A longer duration of heart failure ≥6 years was associated with severe white matter lesions. 700 T. Stegmann et al. ESC Heart Failure 2021; 8: 697–704 DOI: 10.1002/ehf2.13166 20555822, 2021, 1, D ow nloaded from https://onlinelibrary.w iley.com /doi/10.1002/ehf2.13166 by M assey U niversity L ibrary, W iley O nline L ibrary on [21/11/2023]. See the T erm s and C onditions (https://onlinelibrary.w iley.com /term s-and-conditions) on W iley O nline L ibrary for rules of use; O A articles are governed by the applicable C reative C om m ons L icense not statistical significant, while HF remained independently associated with WML (AF: P = 0.701, OR 1.2, 95% CI 0.5–2.8; HF: P = 0.024, OR 2.5, 95% CI 1.1–5.4). Structural and functional echocardiographic parameters and white matter lesions Seven hundred forty-one participants had additional trans- thoracic echocardiography, including 23 of the participants with HF. Mean ejection fraction in HF subjects was 57% (54–62), and only two had a reduced LVEF (<50%). Neither LVEF (OR 0.99, 95% CI 0.83–1.18, P = 0.89) nor left ventricular filling index (E/E′) (OR 0.88, 95% CI 0.63–1.23, P = 0.46), nor left atrial volume indexed to body surface area (OR 1.01, 95% CI 0.96–1.07, P = 0.63) were associated with WML. Heart failure and cognitive testing When LIFE participants without cMRI (n = 6817) were included into the analysis, a long-standing diagnosis of HF was associated with worse results in TMT A (Supporting Infor- mation, Table S1, regression coefficient for TMT A: 3.65, 95% CI 0.56–6.74, P = 0.021). Not significant, but relevant associa- tion with regression coefficient 3.81 (95% CI –5.70–13.31, P = 0.433) could be evaluated for the TMT B (Supporting Information, Table S1). Discussion In this population-based cross-sectional analysis, we found that age, hypertension, stroke, and HF were independently associated with WML. Our results further indicated that a higher Fazekas score of WML was correlated with longer duration of HF, while no significant association was found re- garding the duration of hypertension. However, echocardio- graphic parameters of left ventricular structure and function were not associated with WML. Consistent with our findings, previous studies reported as- sociations of increased systolic blood pressure and age with WML.2,33,34 For instance, a previous study reported an Figure 2 Univariate analysis of atrial fibrillation associated with WML and adjustment for age/gender and age/gender/history of stroke/history of hypertension. Odd’s ratio with 95% confidence interval and the respective P-value are shown. Table 3 Multivariate analysis of hypertension duration and other factors independently associated with white matter lesions (Fazekas 2 and 3) Factors Odds ratio P-value Confidence interval (95%) Gender (female) 1.1 0.603 0.8;1.4 Age 1.1 ≤0.00 1.08;1.12 Stroke 2.2 0.018 1.1;4.1 Hypertension (no vs. ≤3 years after diagnosis) 2.0 0.002 1.3;3.2 Hypertension (no vs. 4–6 years after diagnosis) 2.2 ≤0.001 1.4;3.4 Hypertension (no vs. > 6 years after diagnosis) 1.9 ≤0.001 1.4;2.6 There was no relevant difference between the duration of hypertension and the occurrence of white matter lesions. Heart failure is independently associated with white matter lesions: insights from the population-based LIFE-Adult Study 701 ESC Heart Failure 2021; 8: 697–704 DOI: 10.1002/ehf2.13166 20555822, 2021, 1, D ow nloaded from https://onlinelibrary.w iley.com /doi/10.1002/ehf2.13166 by M assey U niversity L ibrary, W iley O nline L ibrary on [21/11/2023]. See the T erm s and C onditions (https://onlinelibrary.w iley.com /term s-and-conditions) on W iley O nline L ibrary for rules of use; O A articles are governed by the applicable C reative C om m ons L icense increased risk for WML with longer duration of hypertension while we did not observe such an association.35 It is impor- tant to mention that the patients in the LIFE Adult Study may had well-diagnosed and well-controlled hypertension, while poor control of blood pressure was associated with WML.35 Corroborating our data, the history of stroke has pre- viously been associated with WML.7 Heart failure, atrial fibrillation, and correlating brain damage The association between HF and WML has not been analysed in population-based cohorts before. There are only a few studies reporting about HF and correlating structural brain measures in selected HF patients compared with age-matched and gender-matched controls, which lead to strong selection bias.19,20,36 The relation of LVEF with under- lying brain pathology remains controversial because some studies found an independent association between low LVEF and WML, while others did not.1,37 While the exact role of WML for patients with HF with reduced LVEF (HFrEF) remains to be determined, our results indicated a clear association of WML with HF and preserved LVEF (HFpEF). In line with a previous study, we showed that participants with a long-standing (>6 years) diagnosis of HF had more severe WML on cMRI compared with participants without HF or a diagnosis less than 6 years.1 Previous findings reported an association between AF and WML.38,39 For instance, Mayasi et al. retrospectively analysed a cohort with embolic stroke in their medical history (n = 234) and found a significant presence of anterior subcortical WML associated with AF. Contrary to our initial expectations, our results showed no association between AF and WML after adjustment for age, gender, stroke, and hypertension. WML may develop in AF by silent brain infarcts, mostly in patients not on anticoagulation. Heart failure and cognition Considering the cognitive function in patients with HF, com- mon findings are deficits in attention, working memory, and a reduced psychomotor speed.40,41 We observed a significant association between the medical history of HF and worse results in the TMT A, but no significant association with the results of the TMT B. Other studies found similar results where patients with HF had increased task completion time in TMT A as compared with healthy control subjects.16 How- ever, older age was the strongest predictor for worse out- come in cognitive function. Heart failure and cognitive decline are often coexisting in an aging population. However, the exact interaction is challenging, and information about the underlying mecha- nism is lacking. Several proposed pathophysiological path- ways, such as reduced cerebral blood flow,42,43 impaired cerebral autoregulation, and multiple embolic lesions have been considered for the development of WML.1,44 Future studies are needed to investigate the impact of HF treat- ment on structural brain changings including WML alterations. Limitations There are some limitations to consider. The present data only represent a cross-sectional design. Longitudinal follow-up of study participants is underway. Baseline characteristics are strictly based on the medical history reported by the partici- pants. There was no indication to differentiate between sys- tolic or diastolic HF in the questionnaires. Therefore, we may lack data on potentially more individuals with HF, and we were not able to distinguish between participants with HFpEF and participants with previously HFrEF who have now recovered with HF therapy. Moreover, the majority of participants had a preserved LVEF, and our results may be different in subjects with reduced LVEF. The number of patients with HF and the number of patients with stroke was low, limiting the power of our analysis. This is the most likely explanation why only heart failure duration >6 years was independently associated with WML (P = 0.036), while hypertension (which was much more prevalent) showed a consistent odd’s ratio between 1.9 and 2.2 with a very low P-value. Conclusions In a population-based sample, we found an independent association between a history of heart failure, a history of stroke, hypertension, and age with WML on cerebral MRI. More pronounced WML were associated with a longer dura- tion of heart failure. Further studies are needed to investigate if WML can be used as a surrogate marker of cognitive decline in patients with heart failure under heart failure therapy. Acknowledgements This work is supported by LIFE–Leipzig Research Centre for Civilization Diseases, an organizational unit affiliated to the Medical Faculty of the University of Leipzig. LIFE was sup- ported by a research grant by means of the European Union, by the European Regional Development Fund (ERDF), and by funds of the Free State of Saxony within the framework of 702 T. Stegmann et al. ESC Heart Failure 2021; 8: 697–704 DOI: 10.1002/ehf2.13166 20555822, 2021, 1, D ow nloaded from https://onlinelibrary.w iley.com /doi/10.1002/ehf2.13166 by M assey U niversity L ibrary, W iley O nline L ibrary on [21/11/2023]. See the T erm s and C onditions (https://onlinelibrary.w iley.com /term s-and-conditions) on W iley O nline L ibrary for rules of use; O A articles are governed by the applicable C reative C om m ons L icense the excellence initiative. We thank the LIFE Adult study team (‘Data Cluster’, ‘Ambulance Department’, ‘Data Quality Man- agement’, and IT teams) for organizing the course of the study. We thank also the MRI team, especially to Leonie Lampe. Open access funding enabled and organized by Projekt DEAL. Conflict of interest None declared. Funding LIFE (Leipzig Research Centre for Civilization Diseases) is funded by means of the European Union, by the European Regional Development Fund (ERDF) and by funds of the Free State of Saxony within the framework of the excellence initia- tive (project numbers 713-241202, 713-241202, 14505/2470, and 14575/2470). Supporting information Additional supporting information may be found online in the Supporting Information section at the end of the article. Table S1. Multivariate analysis of Trail-Making-Test A and B and other factors independently associated with white mat- ter lesions (Fazekas 2 and 3). References 1. Vogels RLC, van der Flier WM, van Harten B, Gouw AA, Scheltens P, Schroeder-Tanka JM, Henry CW. Brain magnetic resonance imaging abnormalities in patients with heart fail- ure. Eur J Heart Fail 2007; 9: 1003–1009. 2. Vernooij MW. Incidental findings on brain MRI in the general population. N Engl J Med 2007; 357: 1821–1828. 3. Kim KW, MacFall JR, Payne ME. Classifi- cation of white matter lesions on mag- netic resonance imaging in elderly persons. Biol Psychiatry 2008; 64: 273–280. 4. Wardlaw JM, Smith EE, Biessels GJ, Cordonnier C, Fazekas F, Frayne R, Lindley RI, O’Brien JT, Barkhof F, Benavente OR, Black SE, Brayne C, Breteler M, Chabriat H, Decarli C, de Leeuw FE, Doubal F, Duering M, Fox NC, Greenberg S, Hachinski V, Kilimann I, Mok V, Oostenbrugge RV, Pantoni L, Speck O, Stephan BC, Teipel S, Viswanathan A, Werring D, Chen C, Smith C, van Buchem M, Norrving B, Gorelick PB, Dichgans M. STandards for ReportIng Vascular changes on nEuro- imaging (STRIVE v1). Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol 2013; 12: 822–838. 5. de Leeuw F-E. Prevalence of cerebral white matter lesions in elderly people: a population based magnetic resonance imaging study. The Rotterdam Scan Study. J Neurol Neurosurg Psychiatry 2001; 70: 9–14. 6. Verhaaren BJF, Vernooij MW, de Boer R, Hofman A, Niessen WJ, van der Lugt A, Ikram MA. High blood pressure and cerebral white matter lesion progression in the general population. Hypertension 2013; 61: 1354–1359. 7. Debette S, Markus HS. The clinical im- portance of white matter hyperintensities on brain magnetic reso- nance imaging: systematic review and meta-analysis. BMJ 2010; 341: c3666–c3666. 8. Akisaki T, Sakurai T, Takata T, Umegaki H, Araki A, Mizuno S, Tanaka S, Oshashi Y, Iguchi A, Yokono K, Itos H. Cognitive dysfunction associates with white mat- ter hyperintensities and subcortical atro- phy on magnetic resonance imaging of the elderly diabetes mellitus Japanese elderly diabetes intervention trial (J-EDIT). Diabetes Metab Res Rev 2006; 22: 376–384. 9. de Groot JC, de Leeuw FE, Oudkerk M, van Gijn J, Hofman A, Jolles J, Breteler MMB. Cerebral white matter lesions and cognitive function: the Rotterdam Scan Study. Ann Neurol 2000; 47: 145–151. 10. Sachdev P, Wen W, Christensen H, Jorm A. White matter hyperintensities are re- lated to physical disability and poor mo- tor function. J Neurol Neurosurg Psychiatry 2005; 76: 362–367. 11. Prins ND, van DEJ, den HT, Vermeer SE, Koudstaal PJ, Oudkerk M, Hofmann A, Breteler MMB. Cerebral white matter le- sions and the risk of dementia. Arch Neurol 2004; 61: 1531–1534. 12. Prins ND, Scheltens P. White matter hyperintensities, cognitive impairment and dementia: an update. Nat Rev Neurol 2015; 11: 157–165. 13. Brickman AM, Zahodne LB, Guzman VA, Narkhede A, Meier IB, Griffith EY, Provenzano FA, Schupf N, Manly JJ, Stern Y, Luchsinger JA, Mayeux R. Reconsidering harbingers of dementia: Progression of parietal lobe white mat- ter hyperintensities predicts Alzheimer’s disease incidence. Neurobiol Aging 2015; 36: 27–32. 14. Jokinen H, Kalska H, Ylikoski R, Madureira S, Verdelho A, van der Flier WM, Scheltens P, Barkhof F, Visser MC, Fazekas F, Schmidt R, O’Brien J, Walde- mar G, Wallin A, Chabriat H, Pantoni L, Inzitari D, Erkinjuntti T. Longitudinal cognitive decline in subcortical ischemic vascular disease—the LADIS Study. Cerebrovasc Dis Basel Switz 2009; 27: 384–391. 15. Gure TR, Blaum CS, Giordani B, Koelling TM, Galecki A, Pressler SJ, Hummel SL, Langa KM. The prevalence of cognitive impairment in older adults with heart failure. J Am Geriatr Soc 2012; 60: 1724–1729. 16. Vogels RLC, Scheltens P, Schroeder- Tanka JM, Weinstein HC. Cognitive im- pairment in heart failure: A systematic review of the literature. Eur J Heart Fail 2007; 9: 440–449. 17. Sterling MR, Jannat-Khah D, Bryan J, Banerjee S, McClure LA, Wadley VG, Unverzagt FW, Levitan EB, Goyal P, Peterson JC, Manky JJ, Levine DA, Safford M. The prevalence of cognitive impairment among adults with incident heart failure: the “Reasons for geo- graphic and racial fifferences in stroke” (REGARDS) Study. J Card Fail 2019; 25: 130–136. 18. Hajduk AM, Kiefe CI, Person SD, Gore JG, Saczynski JS. Cognitive change in heart failure: a systematic review. Circ Heart failure is independently associated with white matter lesions: insights from the population-based LIFE-Adult Study 703 ESC Heart Failure 2021; 8: 697–704 DOI: 10.1002/ehf2.13166 20555822, 2021, 1, D ow nloaded from https://onlinelibrary.w iley.com /doi/10.1002/ehf2.13166 by M assey U niversity L ibrary, W iley O nline L ibrary on [21/11/2023]. See the T erm s and C onditions (https://onlinelibrary.w iley.com /term s-and-conditions) on W iley O nline L ibrary for rules of use; O A articles are governed by the applicable C reative C om m ons L icense Cardiovasc Qual Outcomes 2013; 6: 451–460. 19. Almeida OP, Garrido GJ, Beer C, Lautenschlager NT, Arnolda L, Flicker L. Cognitive and brain changes associ- ated with ischaemic heart disease and heart failure. Eur Heart J 2012; 33: 1769–1776. 20. Frey A, Sell R, Homola GA, Malsch C, Kraft P, Gunreben I, Morbach C, Alkonyi B, Schmid E, Colonna I, Hofer E, Müllges W, Ertl G, Heuschmann P, Solymosi L, Schmidt R, Störck S, Stoll G. Cognitive deficits and related brain lesions in patients with chronic heart failure. JACC Heart Fail 2018; 6: 583–592. 21. Statistisches Landesamt des Freistaates Sachsen, Ordnungsamt Leipzig (Einwohnerregister). 22. Loeffler M, Engel C, Ahnert P, Alfermann D, Arelin K, Baber R, Beutner F, Binder H, Brähler E, Burkhardt R, Ceglarek C, Enzenbach C, Fuchs M, Glaesmer H, Girlich F, Hagendorff A, Häntzsch M, Hegerl U, Henger S, Hensch T, Hinz A, Holzendorf V, Husser D, Kersting A, Kiel A, Kirsten T, Kratzsch J, Krohn K, Luck T, Melzer S, Netto J, Nüchter M, Raschpichler M, Rauscher FG, Riedel-Heller SG, Sander C, Scholz M, Schönknecht P, Schroeter ML, Simon JC, Speer R, Stäker J, Stein R, Stöbel- Richter Y, Stumvoll M, Tarnok A, Teren A, Teupser D, Then FS, Tönjes A, Treudler R, Villringer A, Weissgerber A, Wiedemann P, Zachariae S, Wirkner K, Thiery J. The LIFE-Adult-Study: objectives and design of a population- based cohort study with 10,000 deeply phenotyped adults in Germany. BMC Public Health 2015; 15: 691. 23. Lampe L, Zhang R, Beyer F, Huhn S, Masouleh SK, Preusser S, Bazin PL, Schroeter ML, Villringer A, Witte V. Visceral obesity relates to deep white matter hyperintensities via in- flammation. Ann Neurol 2019; 85: 194–203. 24. Mariß J, Maurer CJ. Neuroradiologische Messverfahren, Klassifikationen und Zeichen. Stuttgart/New York: Georg Thieme Verlag; 2018; 119–133. 25. Fazekas F, Chawluk J, Alavi A, Hurtig H, Zimmerman R. MR signal abnormalities at 1.5 T in Alzheimer’s dementia and normal aging. Am J Roentgenol 1987; 149: 351–356. 26. Kynast J, Lampe L, Luck T, Frisch S, Arelin K, Hoffmann KT, Loeffler M, Riedel-Heller SG, Villringer A, Schroeter ML. White matter hyperintensities asso- ciated with small vessel disease impair social cognition beside attention and memory. J Cereb Blood Flow Metab 2018; 38: 996–1009. 27. Moms JC, Heyman A, Mohs RC, Hughes JP, van Belle G, Fillenbaum G, Mellits ED, Clark C. The consortium to establish a registry for Alzheimer’s Disease (CERAD). Part I. Clinical and neuropsy- chological assessment of Alzheimer’s dis- ease. Neurology 1989; 39: 1159–1159. 28. Thalmann B, Monsch AU, Schneitter M, Ermini-Fünfschilling D, Spiegel R, Stählin HB. Die CERAD Neuropsycholo gische Testbatterie - Ein gemeinsames minimales Instrumentarium zur Demenzabklärung. Memory Clinic, Geriatrische Universitätsklinik Basel; 1998. http://www.memoryclinic.ch/in- dex.php%3Foption%3Dcom%5Fcontent %26task%3Dblogcategory%26id% 3D11%26Itemid%3D16 29. Reitan RM. The relation of the trail mak- ing test to organic brain damage. J Con- sult Psychol 1955; 19: 393–394. 30. Tischler L, Petermann F. Trail making test (TMT). Z Für Psychiatr Psychol Psy- cho 2010; 58: 79–81. 31. Reitan RM, Wolfson D. Traumatic brain injury. Vol. II. Recovery and rehabilita- tion. Neuropsychology Press, Tucson, AZ; 1988. 32. Collett D. Modelling survival data in medical research. 3rd New ed., Boca Ra- ton: Chapman & Hall/CRC; 2015. 33. Launer LJ. Epidemiology of white mat- ter lesions. Int Psychogeriatr 2003; 15: 99–103. 34. de Leeuw F, de Groot JC, Oudkerk M, Witteman JCM, Hofman A, van Gijn J, Breteler MM. A follow-up study of blood pressure and cerebral white mat- ter lesions. Ann Neurol 1999; 46: 827–833. 35. de Leeuw F-E, de Groot JC, Oudkerk M, Witteman JCM, Hofman A, van Gijn J, Breteler MM. Hypertension and cerebral white matter lesions in a prospective cohort study. Brain 2002; 125: 765–772. 36. Almeida OP, Garrido GJ, Etherton-Beer C, Lautenschlager NT, Arnolda L, Alfonso H, Flicker L. Brain and mood changes over 2 years in healthy controls and adults with heart failure and ischae- mic heart disease. Eur J Heart Fail 2013; 15: 850–858. 37. Schmidt R, Fazekas F, Offenbacher H, Dusleag J, Lechner H. Brain magnetic resonance imaging and neuropsychologic evaluation of patients with idiopathic dilated cardiomyopathy. Stroke 1991; 22: 195–199. 38. de Leeuw FE, de Groot JC, Oudkerk M, Kors JA, Hofman A, van Gijn J, Breteler MMB. Atrial fibrillation and the risk of cerebral white matter lesions. Neurology 2000; 54: 1795–1801. 39. Mayasi Y, Helenius J, McManus DD, Goddeau RP, Jun-O’Connell AH, Moonis M, Henninger N. Atrial fibrilla- tion is associated with anterior pre- dominant white matter lesions in patients presenting with embolic stroke. J Neurol Neurosurg Psychiatry 2018; 89: 6–13. 40. Alagiakrishnan K, Mah D, Ahmed A, Ezekowitz J. Cognitive decline in heart failure. Heart Fail Rev 2016; 21: 661–673. 41. Almeida OP, Flicker L. The mind of a failing heart: a systematic review of the association between congestive heart failure and cognitive functioning. Intern Med J 2001; 31: 290–295. 42. Wardlaw JM, Valdés Hernández MC, Muñoz-Maniega S. What are white mat- ter hyperintensities made of? J Am Heart Assoc Cardiovasc Cerebrovasc Dis 2015; 4: 001140. 43. Alves TCTF, Rays J, Fráguas R, Wajngarten M, Meneghetti JC, Prando S, Busatto GF. Localized cerebral blood flow reductions in patients with heart failure: a study using 99mTc-HMPAO SPECT. J Neuroimaging Off J Am Soc Neuroim 2005; 15: 150–156. 44. Qiu C, Winblad B, Marengoni A, Klarin I, Fastbom J, Fratiglioni L. Heart failure and risk of dementia and alzheimer disease: a population-based cohort study. Arch Intern Med 2006; 166: 1003–1008. 704 T. Stegmann et al. ESC Heart Failure 2021; 8: 697–704 DOI: 10.1002/ehf2.13166 20555822, 2021, 1, D ow nloaded from https://onlinelibrary.w iley.com /doi/10.1002/ehf2.13166 by M assey U niversity L ibrary, W iley O nline L ibrary on [21/11/2023]. See the T erm s and C onditions (https://onlinelibrary.w iley.com /term s-and-conditions) on W iley O nline L ibrary for rules of use; O A articles are governed by the applicable C reative C om m ons L icense http://www.memoryclinic.ch/index.php%3Foption%3Dcom%5Fcontent%26task%3Dblogcategory%26id%3D11%26Itemid%3D16 http://www.memoryclinic.ch/index.php%3Foption%3Dcom%5Fcontent%26task%3Dblogcategory%26id%3D11%26Itemid%3D16 http://www.memoryclinic.ch/index.php%3Foption%3Dcom%5Fcontent%26task%3Dblogcategory%26id%3D11%26Itemid%3D16 http://www.memoryclinic.ch/index.php%3Foption%3Dcom%5Fcontent%26task%3Dblogcategory%26id%3D11%26Itemid%3D16 << /ASCII85EncodePages false /AllowTransparency false /AutoPositionEPSFiles false /AutoRotatePages /None /Binding /Left /CalGrayProfile (Dot Gain 20%) /CalRGBProfile (sRGB IEC61966-2.1) /CalCMYKProfile (U.S. Web Coated \050SWOP\051 v2) /sRGBProfile (sRGB IEC61966-2.1) /CannotEmbedFontPolicy /Error /CompatibilityLevel 1.3 /CompressObjects /Off /CompressPages true /ConvertImagesToIndexed true /PassThroughJPEGImages true /CreateJobTicket false /DefaultRenderingIntent /Default /DetectBlends false /DetectCurves 0.1000 /ColorConversionStrategy /LeaveColorUnchanged /DoThumbnails false /EmbedAllFonts true /EmbedOpenType false /ParseICCProfilesInComments true /EmbedJobOptions true /DSCReportingLevel 0 /EmitDSCWarnings false /EndPage -1 /ImageMemory 1048576 /LockDistillerParams true /MaxSubsetPct 100 /Optimize false /OPM 1 /ParseDSCComments true /ParseDSCCommentsForDocInfo true /PreserveCopyPage false /PreserveDICMYKValues true /PreserveEPSInfo false /PreserveFlatness true /PreserveHalftoneInfo false /PreserveOPIComments false /PreserveOverprintSettings true /StartPage 1 /SubsetFonts true /TransferFunctionInfo /Apply /UCRandBGInfo /Remove /UsePrologue false /ColorSettingsFile () /AlwaysEmbed [ true ] /NeverEmbed [ true ] /AntiAliasColorImages false /CropColorImages true /ColorImageMinResolution 300 /ColorImageMinResolutionPolicy /OK /DownsampleColorImages false /ColorImageDownsampleType /Bicubic /ColorImageResolution 300 /ColorImageDepth 8 /ColorImageMinDownsampleDepth 1 /ColorImageDownsampleThreshold 1.50000 /EncodeColorImages true /ColorImageFilter /FlateEncode /AutoFilterColorImages false /ColorImageAutoFilterStrategy /JPEG /ColorACSImageDict << /QFactor 0.15 /HSamples [1 1 1 1] /VSamples [1 1 1 1] >> /ColorImageDict << /QFactor 0.15 /HSamples [1 1 1 1] /VSamples [1 1 1 1] >> /JPEG2000ColorACSImageDict << /TileWidth 256 /TileHeight 256 /Quality 30 >> /JPEG2000ColorImageDict << /TileWidth 256 /TileHeight 256 /Quality 30 >> /AntiAliasGrayImages false /CropGrayImages true /GrayImageMinResolution 300 /GrayImageMinResolutionPolicy /OK /DownsampleGrayImages false /GrayImageDownsampleType /Bicubic /GrayImageResolution 300 /GrayImageDepth 8 /GrayImageMinDownsampleDepth 2 /GrayImageDownsampleThreshold 1.50000 /EncodeGrayImages true /GrayImageFilter /FlateEncode /AutoFilterGrayImages false /GrayImageAutoFilterStrategy /JPEG /GrayACSImageDict << /QFactor 0.15 /HSamples [1 1 1 1] /VSamples [1 1 1 1] >> /GrayImageDict << /QFactor 0.15 /HSamples [1 1 1 1] /VSamples [1 1 1 1] >> /JPEG2000GrayACSImageDict << /TileWidth 256 /TileHeight 256 /Quality 30 >> /JPEG2000GrayImageDict << /TileWidth 256 /TileHeight 256 /Quality 30 >> /AntiAliasMonoImages false /CropMonoImages true /MonoImageMinResolution 1200 /MonoImageMinResolutionPolicy /OK /DownsampleMonoImages false /MonoImageDownsampleType /Bicubic /MonoImageResolution 1200 /MonoImageDepth -1 /MonoImageDownsampleThreshold 1.50000 /EncodeMonoImages true /MonoImageFilter /CCITTFaxEncode /MonoImageDict << /K -1 >> /AllowPSXObjects false /CheckCompliance [ /PDFX1a:2001 ] /PDFX1aCheck true /PDFX3Check false /PDFXCompliantPDFOnly false /PDFXNoTrimBoxError false /PDFXTrimBoxToMediaBoxOffset [ 0.00000 0.00000 0.00000 0.00000 ] /PDFXSetBleedBoxToMediaBox true /PDFXBleedBoxToTrimBoxOffset [ 0.00000 0.00000 0.00000 0.00000 ] /PDFXOutputIntentProfile (Euroscale Coated v2) /PDFXOutputConditionIdentifier (FOGRA1) /PDFXOutputCondition () /PDFXRegistryName (http://www.color.org) /PDFXTrapped /False /CreateJDFFile false /Description << /CHS /CHT /DAN /DEU /ESP /FRA /ITA (Utilizzare queste impostazioni per creare documenti Adobe PDF che devono essere conformi o verificati in base a PDF/X-1a:2001, uno standard ISO per lo scambio di contenuto grafico. Per ulteriori informazioni sulla creazione di documenti PDF compatibili con PDF/X-1a, consultare la Guida dell'utente di Acrobat. I documenti PDF creati possono essere aperti con Acrobat e Adobe Reader 4.0 e versioni successive.) /JPN /KOR /NLD (Gebruik deze instellingen om Adobe PDF-documenten te maken die moeten worden gecontroleerd of moeten voldoen aan PDF/X-1a:2001, een ISO-standaard voor het uitwisselen van grafische gegevens. Raadpleeg de gebruikershandleiding van Acrobat voor meer informatie over het maken van PDF-documenten die compatibel zijn met PDF/X-1a. De gemaakte PDF-documenten kunnen worden geopend met Acrobat en Adobe Reader 4.0 en hoger.) /NOR /PTB /SUO /SVE /ENG (Modified PDFX1a settings for Blackwell publications) /ENU (Use these settings to create Adobe PDF documents that are to be checked or must conform to PDF/X-1a:2001, an ISO standard for graphic content exchange. For more information on creating PDF/X-1a compliant PDF documents, please refer to the Acrobat User Guide. Created PDF documents can be opened with Acrobat and Adobe Reader 4.0 and later.) >> /Namespace [ (Adobe) (Common) (1.0) ] /OtherNamespaces [ << /AsReaderSpreads false /CropImagesToFrames true /ErrorControl /WarnAndContinue /FlattenerIgnoreSpreadOverrides false /IncludeGuidesGrids false /IncludeNonPrinting false /IncludeSlug false /Namespace [ (Adobe) (InDesign) (4.0) ] /OmitPlacedBitmaps false /OmitPlacedEPS false /OmitPlacedPDF false /SimulateOverprint /Legacy >> << /AddBleedMarks false /AddColorBars false /AddCropMarks false /AddPageInfo false /AddRegMarks false /ConvertColors /ConvertToCMYK /DestinationProfileName () /DestinationProfileSelector /DocumentCMYK /Downsample16BitImages true /FlattenerPreset << /PresetSelector /HighResolution >> /FormElements false /GenerateStructure false /IncludeBookmarks false /IncludeHyperlinks false /IncludeInteractive false /IncludeLayers false /IncludeProfiles false /MultimediaHandling /UseObjectSettings /Namespace [ (Adobe) (CreativeSuite) (2.0) ] /PDFXOutputIntentProfileSelector /DocumentCMYK /PreserveEditing true /UntaggedCMYKHandling /LeaveUntagged /UntaggedRGBHandling /UseDocumentProfile /UseDocumentBleed false >> ] >> setdistillerparams << /HWResolution [2400 2400] /PageSize [612.000 792.000] >> setpagedevice